Agilent expands board to 12, appoints Dr. Otis Brawley, oncology expert

AGILENT TECHNOLOGIES, INC.

Board expanded from 11 to 12 with appointment of Dr. Otis W. Brawley, effective Nov. 17, 2021.
Brawley will serve on Compensation and Nominating/Corporate Governance Committees.
He is Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
Also serves on boards of Incyte Corp., Lyell Immunopharma, and PDS Biotechnology.
Receives standard non-employee director compensation, pro-rated for remainder of 2021.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Otis W. Brawley

Director

A · AGILENT TECHNOLOGIES, INC.

Effective: 2021-11-17
Filed: November 19, 2021, 6:59 PM ET

increased the size of the Board from 11 to 12 members and appointed Otis W. Brawley, M.D., to fill the vacancy so created, both effective November 17, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Otis W. Brawley was appointed as Director at AGILENT TECHNOLOGIES, INC..

Action: appointed
Role: Director

Exact text from the filing

increased the size of the Board from 11 to 12 members and appointed Otis W. Brawley, M.D., to fill the vacancy so created, both effective November 17, 2021.

View on SEC.gov

AGILENT TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001564590-21-057679

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.